Volume | 42,880 |
|
|||||
News | (1) | ||||||
Day High | 0.4357 | Low High |
|||||
Day Low | 0.4001 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Trevena Inc | TRVN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.4045 | 0.4001 | 0.4357 | 0.4045 | 0.407 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
190 | 42,880 | $ 0.4138669 | $ 17,747 | - | 0.3001 - 1.35 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:57:41 | formt | 228 | $ 0.4152 | USD |
Trevena Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
7.69M | 18.32M | - | 3.13M | -40.29M | -2.20 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Trevena News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TRVN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.4289 | 0.4395 | 0.39 | 0.4154883 | 61,429 | -0.0137 | -3.19% |
1 Month | 0.347 | 0.4498 | 0.3227 | 0.3958028 | 94,341 | 0.0682 | 19.65% |
3 Months | 0.5781 | 0.70 | 0.3001 | 0.4434703 | 213,979 | -0.1629 | -28.18% |
6 Months | 0.60 | 0.7693 | 0.3001 | 0.50731 | 151,540 | -0.1848 | -30.80% |
1 Year | 1.31 | 1.35 | 0.3001 | 0.8572244 | 416,019 | -0.8948 | -68.31% |
3 Years | 38.50 | 55.00 | 0.3001 | 15.18 | 1,066,392 | -38.08 | -98.92% |
5 Years | 33.50 | 112.50 | 0.3001 | 39.99 | 1,920,063 | -33.08 | -98.76% |
Trevena Description
Trevena Inc is an American biotechnology company. The portfolio pipeline is focused on medicines targeting pain management: TRV734: oral medicine for moderate to severe pain; TRV250: oral medicine for migraines; and TRV027: treatment for acute heart failure. Its leading product is oliceridine (TRV130), a protein-based chemical meant to manage moderate to severe acute pain. |